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Summary
In many cancers, inactivation of the adenomatous polyposis coli (APC) or Axin tumor suppressor proteins or activating
mutations in -catenin lead to elevated -catenin levels, enhanced binding of -catenin to T cell factor (TCF) proteins,
and increased expression of TCF-regulated genes. We found that the gene for the basic helix-loop-helix transcription
factor ITF-2 (immunoglobulin transcription factor-2) was activated in rat E1A-immortalized RK3E cells following neoplastic
transformation by -catenin or ligand-induced activation of a -catenin-estrogen receptor fusion protein. Human cancers
with -catenin regulatory defects had elevated ITF-2 expression, and ITF-2 was repressed by restoring wild-type APC
function or inhibiting TCF activity. Of note, ITF-2 promoted neoplastic transformation of RK3E cells. We propose that
ITF-2 is a TCF-regulated gene, which functions in concert with other TCF target genes to promote growth and/or survival
of cancer cells with defects in -catenin regulation.
Introduction and its destruction by the proteasome (Jiang and Struhl, 1998;
Winston et al., 1999; Hart et al., 1999; Kitagawa et al., 1999;
Wnt signaling plays a central role in regulating proliferation, Polakis, 2001). Following Wnt pathway activation and inhibition
differentiation, and morphogenesis, and control of -catenin of GSK-3, -catenin accumulates in the cytoplasm and nu-
stability is pivotal in Wnt signaling (reviewed in Cadigan and cleus, where it can bind to members of the TCF (T cell factor)/
LEF (lymphoid enhancer family) transcription factor family (Beh-Nusse, 1997; Peifer and Polakis, 2000; Bienz and Clevers, 2000;
Polakis, 2001). In brief, Wnt ligands activate transmembrane rens et al., 1996; Molenaar et al., 1996) (referred to here collec-
tively as TCFs). In the nucleus, TCFs mediate sequence-specificfrizzled receptors, leading to inhibition of glycogen synthase
kinase-3 (GSK-3) activity. The GSK-3 protein, when active DNA binding, and -catenin, via interaction with TCFs, appears
to have major effects on transcription of genes with TCF bindingand complexed with the APC (adenomatous polyposis coli) and
Axin proteins, can phosphorylate specific serine and/or threo- sites in their regulatory regions (reviewed in Peifer and Polakis,
2000; Bienz and Clevers, 2000; Polakis, 2000).nine residues near -catenin’s amino (N) terminus (Zeng et al.,
1997; Ikeda et al., 1998; Behrens et al., 1998; Yamamoto et al., Defects in Wnt signaling play a major role in human cancer.
Mutations in the -catenin (CTNNB1) gene sequences encoding1998; Polakis, 2001). The phosphorylated forms of -catenin
bind the F box protein -TrCP, a subunit of the SCF-type E3 the crucial GSK-3 phosphorylation sites in -catenin’s
N-terminal domain have been found in many different cancerubiquitin ligase complex, resulting in ubiquitination of -catenin
S I G N I F I C A N C E
A number of TCF-regulated genes in cancer have been suggested. A fraction of the genes, such as c-MYC and cyclin D1, have
been well established to function as oncogenes when deregulated. A few others, such as MMP-7 and gastrin, have been implicated
in the genesis of mouse tumors arising from -catenin deregulation. However, most suggested TCF-target genes have not been
shown to have critical functions in neoplastic transformation in model systems or human cancer. Our findings establish ITF-2 as a
TCF target gene capable of promoting neoplastic transformation of epithelial cells in a fashion akin to mutant -catenin. Moreover,
our data showing that elevated ITF2 expression is linked to mutational defects in -catenin regulation in primary ovarian carcinomas
implicate ITF-2 in human cancer.
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types (Polakis, 2000). In upwards of 70%–80% of colorectal induced neoplastic transformation. In addition to its activation
in RK3E cell lines stably transformed by mutant -catenin, ITF-2cancers and a fraction of other cancers, inactivation of the APC
tumor suppressor gene is the predominant mechanism leading was strongly activated in RK3E cells stably transformed by
-catenin or following ligand-induced activation of a -catenin-to -catenin deregulation (Kinzler and Vogelstein, 1996; Bienz
and Clevers, 2000). In other cancers, mutations in the genes estrogen receptor (ER) fusion protein. Further studies implicated
TCFs and -catenin in regulation of ITF-2 expression in humanencoding one of the two Axin proteins have been reported (Sa-
toh et al., 2000; Liu et al., 2000; Dahmen et al., 2001; Wu et al., cancers. Consistent with the notion that ITF-2 deregulation plays
a vital role in cancers with -catenin defects, aberrant expres-2001). A presumed critical consequence of the Wnt pathway
mutations, whether in the CTNNB1, APC, or AXIN genes, is sion of ITF-2 in RK3E cells promoted neoplastic transformation.
elevation of -catenin levels in the cytoplasm and nucleus. De-
regulation of -catenin leads to constitutive formation of Results
-catenin-TCF complexes and altered expression of TCF target
genes. Proteins encoded by TCF-regulated genes likely cooper- Activation of ITF-2 expression by
- and -catenin in RK3E cellsate in effecting neoplastic transformation. Proposed Wnt/TCF
target genes in cancer cells include known oncogenes, such Our prior studies have shown that N-terminal mutant forms of
-catenin akin to those found in cancers, but not wild-typeas c-MYC (He et al., 1998) and CCND1 (Cyclin D1) (Tetsu and
McCormick, 1999; Shtutman et al., 1999), as well as MMP-7 -catenin, promote neoplastic transformation of RK3E cells
(Kolligs et al., 1999). Unlike-catenin, its close functional relative(matrix metalloproteinase 7/matrilysin) (Crawford et al., 1999),
TCF7 (Roose et al., 1999), PPAR- (peroxisome proliferator- -catenin (also known as plakoglobin) will promote neoplastic
transformation of RK3E cells when overexpressed, without aactivated receptor delta) (He et al., 1999), WISP-1 (Xu et al.,
2000), gastrin (Koh et al., 2000), MDR1 (Yamada et al., 2000), need for N-terminal mutations in the presumptive GSK-3 phos-
phorylation consensus sites to activate -catenin’s transformingAXIN2 (Yan et al., 2001), and survivin (Zhang et al., 2001).
In an effort to better understand the contribution of Wnt/ potential (Kolligs et al., 2000). As noted above, while pilot North-
ern blot studies failed to show that mammalian homologs of-catenin/TCF pathway defects in cancer, we have pursued
efforts to identify potential downstream target genes in RK3E acheate-scute genes were regulated by -catenin in RK3E cells,
we did find that the gene encoding the class I bHLH proteincells, a rat E1A-immortalized epithelial cell line that can be neo-
plastically transformed by mutant -catenin (Kolligs et al., 1999). ITF-2 was activated in -catenin-transformed RK3E cell lines.
To establish the significance of this observation, additionalStudies in Drosophila have implicated the Wnt pathway in regu-
lating the proneural acheate-scute genes (Couso et al., 1994; Northern blot studies of ITF-2 expression were carried out on
RNA from a larger panel of cell lines, including parental RK3EGonza´lez-Gaita´n and Ja¨ckle, 1995; Johnston and Edgar, 1998;
Wan et al., 2000), which encode basic helix-loop-helix (bHLH) cells, nine independent -catenin-transformed RK3E lines, and
nine independent -catenin transformed lines. ITF-2 expressiontranscription factors. In Northern blot studies in RK3E cells, we
failed to find evidence that mammalian homologs of acheate- was markedly and consistently increased in - and -catenin
transformed RK3E lines, ranging from 2.4- to 11.6-fold greaterscute were regulated by -catenin. Because of their role in
regulating the activity of acheate-scute-type bHLH proteins, we than the levels seen in parental RK3E cells (Figure 1A). The
observation that ITF-2 expression was not increased in RK3Epursued pilot studies of the expression of genes encoding class
I or “E type” bHLH proteins. The four class I bHLH proteins cells transformed by mutant K-ras (RK3E/K-ras) suggested that
increased expression in - and -catenin-transformed lines didplay important roles in cell growth and differentiation. They are
characterized by a broad expression pattern and the capability not simply reflect their neoplastic phenotype. An analysis of the
time course of ITF-2 induction following infection of RK3E cellsof forming homodimers as well as heterodimers with other
classes of bHLH proteins (reviewed in Murre et al., 1994; Atchley with retroviruses encoding the S33Y oncogenic form of
-catenin or a control -galactosidase protein showed thatand Fitch, 1997; Massari and Murre, 2000). Following dimeriza-
tion, the bHLH proteins can recognize a consensus DNA se- ITF-2 expression was induced roughly concordant with accu-
mulation of exogenous -catenin protein in the cells (Figure 1Bquence termed an E box (i.e., 5-CANNTG-3). Dimerization is
mediated via the HLH domain, whereas DNA binding is con- and data not shown). Consistent with the view that -catenin
activates ITF-2 expression via TCF-dependent mechanisms, in-ferred by the basic region. In contrast to class I bHLH proteins,
class II bHLH proteins typically show tissue-specific expression duction of ITF-2 by -catenin was clearly inhibited in an RK3E
cell line stably expressing a dominant negative mutant form ofpatterns and a stronger potential for forming heterodimers with
E proteins than for forming homodimers (Murre et al., 1994; TCF-4 (i.e, RK3E/Tcf-4N31 cells; Figure 1B).
To confirm the link between activation of -catenin andMassari and Murre, 2000). A related class of proteins, commonly
named Ids, lacks the DNA binding domain but still efficiently induction of ITF-2 expression, we utilized an RK3E cell line
expressing a chimeric -catenin-estrogen receptor (ER) fusiondimerizes with E proteins via the HLH motif (reviewed in Massari
and Murre, 2000; Norton, 2000). The Ids are presumed to nega- protein (RK3E/S33Y-ER), in which full-length S33Y -catenin
sequences had been cloned upstream of a mutated estrogentively regulate differentiation pathways by sequestering E pro-
teins, thereby inhibiting formation of heterodimers of E proteins receptor ligand binding domain capable of binding 4-hydroxyta-
moxifen (4-OHT) but not estrogen (Littlewood et al., 1995). Fol-and tissue specific bHLH-proteins.
Intriguingly, we found that the gene encoding the class I lowing treatment of the RK3E/S33Y-ER cell line with 4-OHT,
gel shift and reporter gene assays indicated that -catenin/TCFbHLH protein ITF-2 (immunoglobulin transcription factor) (also
known as E2-2, SEF-1 and Tcf-4 [for transcription factor 4]; complexes and elevated TCF transcriptional activity could first
be detected between 6–12 hr (Figure 2C and data not shown).hereafter referred to as ITF-2) showed reproducibly and signifi-
cantly increased expression in RK3E cells following -catenin- ITF-2 transcripts were increased roughly 1.5-fold over control
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Figure 2. ITF-2 is a direct target of -catenin in RK3E cells
A: Time course of ITF-2 induction in the RK3E/S33Y-ER cell line following
exposure to 4-OHT to activate the S33Y -catenin/ER chimeric protein.
Northern blot analysis was performed on total RNA isolated at the indicated
time points. B: Induction of ITF-2 following -catenin activation by 4-OHTFigure 1. Activation of ITF-2 expression by - and -catenin in RK3E cells
treatment does not require new protein synthesis. Northern blot analysis of
A: Northern blot studies of ITF-2 expression were carried out on RNA from
ITF-2 expression in RK3E/S33Y-ER cells in control conditions or following a 12
parental RK3E cells, a polyclonal RK3E line transformed by mutant K-ras
hr exposure to 4-OHT and/or cycloheximide. Following hybridization to the
(RK3E/K-ras), and 18 independent clonal RK3E cell lines stably transformed
ITF-2 probe, the blots were stripped and rehybridized to a GAPDH probe.
by - or -catenin. B: Northern blot studies of ITF-2 expression at various
The level of ITF-2 expression in each sample, after normalization for the
time points following infection of RK3E/Neo and RK3E/Tcf-4N31 cells with
GAPDH signal, is indicated below the respective lane. The largest and most
retroviruses containing the indicated cDNAs for S33Y -catenin and LacZ
intense band detected on the ITF-2 Northern blots, corresponding to ITF-2B
(-galactosidase). RNA from clonal RK3E lines stably transformed by
isoform transcripts, was quantified and is shown in the figure. C: Time course
-catenin (RK3E/S33Y-C and RK3E/S33Y-D) are shown at the right. To
of TCF reporter gene activation in the RK3E/S33Y-ER cell line. 24 hr after
assess loading and transfer, the blots were stripped and hybridized to a
transfection with the pTOPFLASH (T) or pFOPFLASH (F) reporter gene con-
GAPDH probe. The levels of ITF-2 expression in each cell line, after normaliza-
structs, cells were either sham treated () or exposed to 4-OHT () for the
tion for the GAPDH signal, are indicated below the respective lanes, with
indicated time periods, prior to harvesting the cells for luciferase assays. The
values relative to those in parental RK3E cells (A) or day 1 post-infection of
means and standard deviations of light units detected in two independent
S33Y-catenin infected RK3E/Neo cells (B). The largest and most intense
experiments performed in duplicate are shown.
band detected on the ITF-2 Northern blots, corresponding to ITF-2B isoform
transcripts, was quantified and is shown in the figure.
Repression of ITF-2 expression by APC
and dominant negative TCF-4levels after 12 hr of 4-OHT treatment to more than 2-fold over
As noted above, inactivating mutations in the APC gene arecontrol levels during the time course studied (Figures 2A and
seen in about 70%–80% of human colon cancers, and the2B and data not shown). Consistent with the notion that ITF-2
defects lead to -catenin deregulation and constitutive activa-
is a “direct” or primary target gene regulated by -catenin,
tion of-catenin/TCF transcripton (Kinzler and Vogelstein, 1996;
blockade of new protein synthesis by cycloheximide treatment
Bienz and Clevers, 2000). To explore the relationship between
did not inhibit the induction of ITF-2 at the 12 hr time point (Figure
-catenin deregulation and ITF-2 expression in human colon
2B). More extended treatment of the cells with cycloheximide cancer, we took advantage of a colon cancer cell line with tightly
resulted in cell death. The induction of ITF-2 transcripts following regulated expression of an exogenous copy of the wild-type
4-OHT treatment may be perceived as delayed relative to that APC gene. The HT29 colon cancer line has truncating mutations
expected for a direct target gene. However, because TCF activ- in both APC alleles, and a variant HT29 line (HT29/APC) has
ity is not strongly activated in the RK3E/S33Y-ER cell line until been generated in which, following zinc treatment, expression
about 12 hr after 4-OHT treatment, and the ITF-2 transcriptional of an exogenous wild-type APC protein is rapidly induced to
unit is very large (350 kilobases; see below), requiring more roughly the same level as that of the endogenous truncated APC
than 3 hr to transcribe, these factors may contribute to the proteins (Morin et al., 1995). Using real-time RT-PCR assays to
apparent delay in ITF-2 transcript accumulation after 4-OHT study gene expression at various time points following zinc
treatment of the HT29/APC cells and a matched control linetreatment.
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on examination of the human genomic DNA sequence, the
ITF-2B transcriptional unit spans greater than 350 kilobases.
Transcripts for the two isoforms appear to arise as the result
of alternative promoter usage, with the 5-most exon for the
shorter ITF-2A isoform located within what appears to be intron
7 of the transcriptional unit for the longer ITF-2B isoform. Our
real-time RT-PCR studies in the HT-29 and DLD-1 colon cancer
cell lines indicated that restoration of APC function or expression
of dnTCF-4 significantly reduced ITF-2B transcript levels, but
had very modest effects on the levels of ITF-2A transcripts
(Figure 3 and data not shown). Although the start site for human
ITF-2B transcripts has not been mapped, a search of the geno-
mic sequences flanking exon 1 of the ITF-2B transcriptional unit
identified several potential TCF binding sites upstream of exon
1 (Figure 4A). Cloning of rat genomic ITF-2 sequences and
analysis of the 5 extent of ITF-2B transcripts in -catenin-
transformed RK3E cells revealed the presence of potential TCF
binding sites upstream of rat ITF-2B exon 1.
Luciferase reporter gene constructs containing sequences
from the presumptive human and rat ITF-2B promoters were
generated, along with analogous constructs containing muta-
tions in proximal potential TCF binding sites. We found that
-catenin could stimulate luciferase activity of the rat reporter
gene constructs containing wild-type TCF elements (i.e., con-
structs rITF2	 and rTF2; Figure 4B), but not constructs with
deletion or mutation of a proximal TCF binding site (i.e., con-
structs rITF2 and rITF2; Figure 4B). Similar to the findingsFigure 3. Repression of ITF-2B expression in colon cancer cells by APC and
dominant negative TCF-4 obtained in studies of other candidate -catenin/TCF regulated
genes, such as c-MYC (He et al., 1998), CCND1 (Tetsu andA: Quantitative real-time (TaqMan) RT-PCR analysis of ITF-2B expression at
various time points following ZnCl2 treatment (tx) of HT-29 cells with Zn- McCormick, 1999), and MMP-7 (Crawford et al., 1999), the rat
inducible APC expression (HT-29/APC) or HT-29 cells with Zn-inducible ITF-2B promoter was only modestly responsive to -catenin in
-galactosidase (HT-29/Gal). Following normalization for HPRT expression, cells with otherwise intact -catenin/TCF function (i.e., 293the data are plotted as the fold decrease in ITF-2B expression relative to
cells). Therefore, we sought to obtain additional evidence sup-the control time point (0 hr). B: Real-time RT-PCR analysis of ITF-2B expression
in HT-29 and DLD1 colon cancer cells stably expressing a dominant negative porting the role of -catenin and TCFs in regulating the ITF-2B
form of TCF-4 (dnTCF-4) or control empty expression vector cassette (vector promoter. As such, the transcriptional activity of the human
only). Following normalization for HPRT expression, data are plotted as the ITF-2B 5 flanking region was assessed in colon cancer cell
fold decrease in ITF-2B expression, with the control (vector only) assigned
lines that had deregulated TCF transcription resulting from ana value of 1.
oncogenic mutation in -catenin (HCT-116) or APC inactivation
(SW480) (Morin et al., 1997). The wild-type human ITF-2B re-
porter construct (i.e., hITF2	) had strong activity in HCT-116
and SW480 cells relative to the TCF-dependent TOPFLASH(i.e., HT29/-Gal), we found that ITF-2 expression was strongly
reporter construct, and this activity could be significantly inhib-suppressed by APC induction (Figure 3A). Zinc treatment of the
ited by cotransfection of the dnTCF-4 expression construct (Fig-control HT29/-gal cell line had no detectable effect on ITF-2
ure 4C). The activity of the hITF2 reporter construct containingexpression (Figure 3A). TCFs seem to play an important role in
mutations in a proximal TCF binding element was substantially-catenin’s ability to regulate ITF-2 expression in colon cancer,
reduced compared to the ITF2	 construct in both HCT-116as ITF-2 expression was reduced in both HT-29 and DLD-1
and SW480 cells, and its activity was nominally affected bycolon cancer cells by expression of a dominant negative form
cotransfection of the dnTCF-4 construct (Figure 4C). Taken to-of TCF-4 (dnTCF-4), in which the N-terminal -catenin binding
gether, the data from the studies of the rat and human ITF-2Bregion of TCF4 had been deleted (Figure 3B).
promoters suggest that proximal TCF binding elements play a
key role in -catenin’s ability to activate ITF-2B expression in-catenin activates ITF-2B transcription via a TCF
cancer cells.site in the proximal promoter
Based on sequence analysis, the human ITF-2 gene maps to
Increased ITF-2B expression in cancerschromosome 18q21, and transcripts encoding multiple isoforms
with -catenin defectsof the protein have been described (Henthorn et al., 1990; Cor-
Many of the candidate -catenin/TCF-regulated genes de-neliussen et al., 1991; Skerjancet al., 1996; Liu et al., 1998).
scribed in the literature have been proposed based largely onTwo of the major isoforms, ITF-2A and ITF-2B, differ at their
data from in vitro and/or animal model studies. To date, only aN termini, but share identity over the majority of their extent,
few studies have assessed expression of candidate -catenin/including the bHLH region. Specifically, the predicted 667 amino
TCF target genes in collections of primary human tumors thatacid ITF-2B isoform shares the carboxyl-terminal 483 amino
acids with the predicted 510 amino acid ITF-2A isoform. Based have been thoroughly characterized for mutational defects in
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Figure 4. Role of TCF elements in the rat and hu-
man ITF-2B promoters in regulating transcrip-
tional activity
A: Schematic diagram of rat and human ITF-2B
promoter regions, indicating location of 5exons,
candidate TCF binding sites, and the extent of
the rat and human ITF-2 sequences cloned into
the pGL3basic luciferase reporter vector. The
designation for the 4 rat and 2 human ITF2 re-
porter constructs and the status (wild-type or mu-
tated) of candidate TCF binding sites in the con-
structs are noted. The transcriptional initiation
sites for rat and human ITF-2B have not been
definitively mapped. Position 1 in the rat ITF-
2B promoter was designated as the nucleotide
immediately upstream of the 5 end of a rat 5
RACE product. For the human ITF-2B promoter,
1 was designated as the nucleotide immedi-
ately upstream of the 5-most nucleotide present
in the human ITF-2B cDNA sequence in the Gen-
Bank accession. However, based on the activity
of the hITF2	 reporter construct, promoter ele-
ments and transcriptional initiation appear to be
considerably upstream of 1. The direction of
the arrows indicates the strand on which the
candidate TCF binding elements were detect-
ed. The underlined nucleotide(s) indicate the
mutations present in the mutated rat and hu-
man reported constructs. B: Effects of -caten-
in on rat ITF2 reporter gene constructs in 293 cells.
The relative activity of control pGL3basic and rat
ITF2 constructs shown in A was assessed following
transient transfection of the cells with a pcDNA3
expression construct encoding S33Y -catenin.
The fold induction by -catenin relative to co-
transfection with empty pcDNA3 vector is shown.
The means and standard deviations of three in-
dependent experiments are shown. C: Activity
of human ITF2 reporter constructs and their re-
sponse to dominant negative TCF-4 (dnTCF-4) in
human HCT116 and SW480 colon cancer cells.
The reporter gene transfected is indicated along
with whether dnTCF-4 was cotransfected. In all
assays, the amount of DNA transfected was kept
constant by cotransfection of empty vector, if
required. The means and standard deviations of
the light units detected in two independent ex-
periments performed in duplicated are shown.
-catenin regulation (Takayasu et al., 2001; Yan et al., 2001). data not shown), we found a statistically significant increase in
the levels of ITF-2A and ITF-2B transcripts when comparingWe examined ITF-2 expression in primary ovarian endometrioid
adenocarcinomas (OEAs), because, while OEAs share very OEAs with -catenin regulatory defects to OEAs with intact
-catenin regulation (P 
 0.048 for ITF-2A and P 
 0.0026 forcomparable histological features, only about 30%–40% of the
lesions have mutational defects affecting -catenin regulation ITF-2B). In addition to the fact that the data showed greater
statistical significance for ITF-2B, the magnitude of the increase(Gamallo et al., 1999; Saegusa and Okayasu, 2001; Wu et al.,
2001). This contrasts with the situation in primary colorectal in ITF-2B transcripts in tumors with -catenin defects was far
greater than that observed for ITF-2A (Figure 5).carcinomas, which nearly always carry mutational defects in
-catenin regulation (Kinzler and Vogelstein, 1996; Bienz and Immunohistochemistry studies with polyclonal antibodies
raised against sequences shared by both ITF-2A and ITF-2BClevers, 2000). As such, comparison of gene expression in OEAs
with intact -catenin regulation versus OEAs with defective were carried out on a subset of the OEAs studied in the real-time
RT-PCR analysis. In six of eight OEAs with -catenin regulatory-catenin regulation should permit a more definitive evaluation
to be made regarding the relationship between-catenin regula- defects and elevated ITF-2B gene expression, moderate to
strong reactivity for ITF-2 was seen in the nuclei of the carcinomatory defects and expression of candidate -catenin/TCF target
genes. Using real-time RT-PCR assays to assess ITF-2A and cells (examples shown in Figures 6B–6E). Studies of adjacent
sections from selected cases using antibodies against-cateninITF-2B expression in a group of 45 OEAs previously character-
ized for -catenin nuclear localization and mutations in the and ITF-2 demonstrated concordant nuclear staining patterns
for the two antibodies (Figures 6A and 6B), though, as found-catenin, APC, AXIN1, and AXIN2 genes (Wu et al., 2001 and
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induce morphological transformation of RK3E cells (Kolligs et
al., 1999, 2000), focus formation by ITF-2B was not detectably
inhibited in RK3E cells that stably overexpressed the dnTCF-4
mutant protein (Figures 7D and 7E). While parental RK3E cells
are incapable of forming colonies in soft agar (i.e., anchorage-
independent growth), 13 of 21 independent clonal cell lines
established from ITF-2B transformed RK3E foci showed robust
growth in soft agar, with colony forming abilities in agar akin to
those seen in -catenin-tranformed RK3E lines (data not
shown). Taken together, the data establish that ITF-2B can in-
duce neoplastic transformation in epithelial cells when deregu-
lated, and it likely plays an important role in the neoplastic
Figure 5. ITF-2B expression is markedly increased in ovarian endometrioid phenotype of cancer cells with -catenin regulatory defects.
adenocarcinomas (OEAs) with -catenin regulation defects
cDNA preparations from snap-frozen OEA specimens that had been pre-
Discussionviously studied for -catenin immunohistochemistry ,and mutations in critical
Wnt pathway components (-catenin, APC, AXIN1, and AXIN2) were sub-
jected to quantitative real-time (TaqMan) analysis of ITF-2A and ITF-2B ex- Mutations in critical components of the Wnt pathway, including
pression. Following normalization for HPRT expression, data are plotted show- -catenin, APC, and the Axins, play a prominent role in the
ing the relative levels of ITF-2A and ITF-2B expression in the 18 tumor samples pathogenesis of human cancer (reviewed in Polakis, 2000; Bienz
with strong nuclear staining for -catenin and mutations in the -catenin,
and Clevers, 2000). Arguably, perhaps the key consequence ofAPC, AXIN1, or AXIN2 genes (i.e., -catenin Reg [Regulation] Defect) versus
the loss-of-function mutations in APC and the Axins or the gain-the levels of ITF-2A and ITF-2B expression in the 27 OEAs lacking strong
nuclear -catenin staining and pathway mutations (i.e., -catenin Reg In- of-function mutations in -catenin is to elevate -catenin levels
tact). in the cytoplasm and nucleus. As a result of its dysregulation,
-catenin shows increased ability to bind to TCFs, and altered
transcription of TCF-regulated genes ensues. Thus far, it ap-
pears that activation of -catenin/TCF-regulated target genes
previously (Wu et al., 2001), the -catenin antibody often predominates following Wnt pathway deregulation in cancer,
showed strong cytoplasmic staining along with nuclear staining and a number of -catenin/TCF target genes in cancer have
(Figure 6A). Six of the seven OEAs with intact -catenin regula- been proposed.
tion showed virtual absence of ITF-2 immunoreactivity in the We have presented data here implicating ITF-2, particularly
nuclei of carcinoma cells, while the remaining case showed transcripts encoding the ITF-2B isoform, as a downstream tar-
weak nuclear staining for ITF-2 (examples in Figure 6F–6H). get of the Wnt/-catenin/TCF pathway. We found that the rat
The immunohistochemistry results offer further support for the ITF-2 gene was consistently activated in - and -catenin trans-
notion that defects in -catenin regulation lead to significant formed RK3E cells, and that 4-OHT-induced activation of a
alterations in ITF-2 expression in primary human cancers. -catenin-ER fusion protein stimulated ITF-2 expression, even
when new protein synthesis was blocked, suggesting that ITF-2
ITF-2B promotes neoplastic transformation is a direct target of -catenin in the nucleus. Based on studies
As described above, cancer-derived mutant forms of -catenin, with a dominant negative form of TCF-4 and reporter gene
but not wild-type -catenin, will readily generate foci of morpho- constructs containing sequences from the region where ITF-2B
logically transformed cells when introduced into the RK3E E1A- transcripts initiate, evidence was obtained that TCFs play a
immortalized rat epithelial cell line, and the ability of -catenin prominent role in -catenin’s ability to induce ITF-2 transcrip-
to induce neoplastic transformation in RK3E is dependent on tion. Moreover, primary ovarian carcinomas with defective
intact TCF function (Kolligs et al., 1999). In our studies, several -catenin regulation were found to have elevated ITF-2B gene
candidate -catenin/TCF target genes, including c-MYC and and protein expression when compared to an essentially analo-
WISP-1, have not shown focus-forming activity in RK3E cells gous group of ovarian carcinomas with intact regulation of
(F.T.K. and E.R.F., unpublished data), though the result for -catenin.
c-MYC may be attributable to the fact that the presence of E1A Thus far, a quite sizeable number of -catenin/TCF-regu-
in RK3E cells renders c-MYC redundant. Nevertheless, given lated genes in cancer have already been proposed. Neverthe-
the utility of the RK3E system for assessing the transforming less, our data implicating ITF-2 as a -catenin/TCF target gene
activity of -catenin and the evidence that ITF-2B is a -catenin/ are of particular interest. First, the vast majority of the candidate
TCF-regulated target gene, we sought to determine if ITF-2B -catenin/TCF-regulated genes have not been carefully as-
had focus-forming activity in RK3E. Consistent with our prior sessed in a large collection of primary human cancers that are
studies (Kolligs et al., 1999, 2000), replication-defective retrovi- well characterized for mutational defects in-catenin regulation.
ruses expressing the control LacZ gene failed to induce foci in As such, it is notable that we found that elevated ITF2 expression
RK3E cells, and retroviruses expressing the S33Y mutant form was intimately linked to mutational defects in -catenin regula-
of -catenin induced more than 300 foci (Figures 7A, 7B, and tion in primary ovarian carcinomas. Second, only a minority of
7E). Remarkably, replication-deficient retroviruses expressing the -catenin/TCF target genes described to date have been
ITF-2B generated foci of morphologically transformed cells in implicated as important factors in neoplastic transformation.
RK3E, albeit with an efficiency roughly one-third that of S33Y Two of the candidate TCF targets—c-MYC and cyclin D1—have
-catenin retroviruses (Figures 7C and 7E). Unlike -catenin been well established to function as oncogenes when deregu-
lated in various settings (reviewed in Sherr, 1996; Dang, 1999),and -catenin, which are dependent on intact TCF function to
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Figure 6. Immunohistochemical staining reveals
increased nuclear ITF-2 expression in OEAs with
-catenin regulatory defects compared to OEAs
with intact -catenin regulation
Paraffin-embedded sections were obtained
from OEA tumor specimens that had been pre-
viously analyzed for ITF-2A and ITF-2B gene ex-
pression, using real-time RT-PCR (Figure 5). The
OEA specimens had also been previously stud-
ied for -catenin immunohistochemistry and mu-
tations in critical Wnt pathway components.
Photomicrographs are shown of the -catenin
(A) and ITF-2 (B) staining seen in serial sections
of an OEA specimen carrying an oncogenic
-catenin mutation. Representative photomi-
crographs of ITF-2 staining in other OEAs with de-
fective -catenin regulation (C–E) and intact
-catenin regulation (F–H) are also shown. Note
that the nuclear staining for ITF-2 seen in the neo-
plastic cells of OEAs with -catenin regulation
defects was lacking in OEAs with intact-catenin
regulation, though faint cytoplasmic staining
was seen in neoplastic cells of some specimens
(e.g., G and H).
and it is presumed, but not yet proven, that they play significant capable of inducing transformation of RK3E cells expressing a
dominant negative mutant of TCF-4. Other candidate -catenin/roles when activated in cancers with -catenin regulation de-
fects. Two other TCF target genes, namely MMP-7 and gastrin, TCF-regulated genes that we have studied, including c-MYC
and WISP-1, have not shown focus-forming activity in RK3Ethough not known to be oncogenes based on in vitro or trans-
genic animal studies, have been implicated via genetic ap- cells (F.T.K. and E.R.F., unpublished data), though c-MYC’s
function as an oncogene in vivo is not in question (Dang, 1999)proaches as significant factors in adenoma formation in mice
carrying germline Apc defects (Wilson et al., 1997; Koh et al., and WISP-1 will mediate transformation in certain settings (Xu
et al., 2000).2000). In light of the rather limited data on the role of candidate
TCF target genes in the cancer process, our findings showing ITF-2 is one of four members of the mammalian class I bHLH
proteins (Murre et al., 1994; Massari and Murre, 2000). The otherthat ITF-2B, like mutated -catenin, has the ability to induce
morphological transformation and anchorage-independent three are HEB and the differentially spliced products of the E2A
gene, E12 and E47. The class I bHLH proteins display a broadgrowth in RK3E cells is noteworthy. As would be predicted
for a downstream target of -catenin/TCF, ITF-2B was readily expression pattern, and they are presumed to bind DNA as
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by concordant increases in binding of bHLH proteins to E box
sites is critical for differentiation (reviewed in Massari and Murre,
2000; Norton, 2000). Consistent with this model, enhanced ex-
pression of Id proteins appears to enhance cell proliferation in
several systems. Interestingly, Id-2 is a presumptive down-
stream target of -catenin/TCF in colon cancer (Rockman et al.,
2001). Id-2’s positive role in promoting growth and/or survival in
certain settings may be via mechanisms independent of its role
in binding to bHLH proteins (Iavarone et al., 1994; Norton, 2000).
Our data implicating ITF-2B as -catenin/TCF-regulated on-
cogene in epithelial cells are rather unexpected, because prior
studies had largely implicated ITF-2 and the other class I bHLH
proteins in lineage commitment and differentiation, not onco-
genesis (Massari and Murre, 2000). However, altered function
of class I and II bHLH proteins has previously been linked to
cancer development, since translocations fusing the amino-
terminal activation domain of the E2A gene to other transcription
factors are seen in B cell leukemias, and translocations activat-
ing expression of the class II bHLH proteins SCL/Tal1 and Lyl1
are seen in T cell leukemias (Look, 1997; Massari and Murre,
2000). On the surface, the observation that both Id-2 and ITF-2B
appear to be downstream targets of -catenin/TCF signaling in
cancer seems curious. Specifically, because ITF-2 can bind to
Id-2, the induction of both proteins by -catenin/TCF signaling
might be predicted to antagonize Id-2’s potential role in growth
promotion, cell survival, and cancer. Clearly, the interactions
among bHLH proteins, Ids, and other non-HLH proteins are
complex (Massari and Murre, 2000; Norton, 2000). Additionally,
there are many uncertainties about the levels and patterns of
expression of class I and class II bHLH proteins and Ids in
cancer cells with -catenin regulatory defects. Given these con-
siderations, it is probably premature to attempt a simple recon-
ciliation of the finding that both Id-2 and ITF-2B are -catenin/
TCF target genes in cancer. Moreover, in light of the important
contributions of cell context to phenotypic effects observed, it
seems likely that there will be many exceptions to generaliza-
tions about the primary role of Id activation in promoting prolifer-
ation and the primary role of class I bHLH proteins in lineage
commitment and differentiation (Ishiguro et al., 1996; NortonFigure 7. Neoplastic transformation of RK3E cells by ITF-2B
and Atherton, 1998; Chen et al., 1999; Massari and Murre, 2000;RK3E cells (A–C) or RK3E/dnTCF-4 (aka RK3E/Tcf-4N31) cells (D) were in-
Norton, 2000; Parrinello et al., 2001). In fact, because two offected with replication-defective retroviruses containing LacZ, S33Y
-catenin, or ITF-2B cDNAs. Four weeks after infection with the retroviruses, the major isoforms of ITF-2—ITF2A and ITF2B—have distinct
the plates were fixed, stained, and photographed. In E, the number of N termini and apparently distinct functions (Skerjanc et al., 1996;
foci (mean and standard deviation) counted in two or more independent
Petropoulos and Skerjanc, 2000), a proposition also supportedexperiments with the indicated constructs is shown.
by their differential regulation by alternative promoters, even
generalizations about ITF-2 function, without consideration of
the specific isoform of ITF-2 involved, may be unwise. Further
studies will undoubtedly enhance understanding of the specifichomodimers or following dimerization with one of the many
mechanisms by which increased expression of ITF-2B contrib-tissue-specific (class II) bHLH proteins, such as the myogenic
utes to cancer.regulatory factors (e.g., MyoD, MRF-4), heart-specific bHLHs
(e.g., dHAND and eHAND), pancreas bHLHs (e.g., BETA2/
Experimental procedures
NEUROD), or neurogenic bHLHs (e.g., MASH-1, Math1, neuro-
genin) (Massari and Murre, 2000). The Id proteins, because they Plasmids
have the HLH dimerization motif but lack the basic DNA binding Retroviral and/or pcDNA3 expression vectors for mutant -catenin (codon
33 substitution of tyrosine for serine—S33Y), dominant negative Tcf-4 (Tcf-region, can inhibit the function of the class I bHLH proteins
4N31), and -galactosidase (LacZ gene) have been described (Kolligs et(Benezra et al., 1990; Massari and Murre, 2000; Norton, 2000).
al., 1999). The pBabe-S33Y-ER-puro expression vector encoding a chimericOf the four mammalian Id proteins, two (Id-1 and Id-3) seem to
-catein/ER protein, in which full-length S33Y -catenin sequences are fused
be broadly expressed, whereas the other two (Id-2 and Id-4) in-frame to a mutated ER ligand binding domain, was generated by cloning
show more restricted patterns of expression. It has been sug- the S33Y -catenin cDNA into the retroviral plasmid pBABE-puro (Littlewood
et al., 1995). pBABE-puro was generously provided by Dr. A. Friedmangested that downregulation of Id gene expression accompanied
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(Johns Hopkins University). The reporter constructs pTOPFLASH, which the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was also
generated by PCR-based approaches, and both the rat ITF-2 and GADPHcontains three copies of an optimal TCF binding motif (CCTTTGATC), and
pFOPFLASH, which contains three copies of a mutant motif (CCTTTGGCC), fragments were labeled with 32P by random priming. Northern blot hybridiza-
tion to 32P-labeled probes was carried out by standard methods. Signalshave been described (Korinek et al., 1997). Plasmid pCH110 (Pharmacia
Biosciences, Piscataway, NJ) contains a functional LacZ gene cloned down- were detected by exposure to BioMax-MS film (Kodak, Rochester, NY)
at 80C with an intensifying screen. Quantitation of signals was performedstream of a cytomegalovirus early-region promoter-enhancer element. Rat
ITF-2B promoter fragments were isolated from a rat genomic library by by densitometry.
standard methods, using as a hybridization probe a 250 bp fragment of
rat ITF-2B cDNA, beginning 550 bp upstream of the start codon. Specific Real-time RT-PCR assays
promoter fragments were then generated by PCR from a 4.5 kb subclone Total RNA from cell lines and primary ovarian endometroid adenocarcinomas
(OEAs) was treated with RNase-free DNase (Life Technologies, Inc.), andfrom the genomic library screen and ligated into pGL3basic vector (Promega,
first strand cDNA was synthesized using random hexamers (Pharmacia Bio-Madison, WI) for luciferase reporter gene assays. The rat ITF-2B cDNA
sciences) and Superscript II reverse transcriptase (Life Technologies, Inc.).sequence and 5 genomic flanking sequences were used in BLAST searches
For PCR with the Prism 7700 Sequence Detector (Applied Biosystems,to identify the presumptive promoter region for human ITF-2B. Specific
Foster City, CA), 5 ng of cDNA from each sample was used in each reaction.human ITF-2 genomic fragments were generated by PCR using sequences
The forward primer for ITF-2A was: 5-ACTATAATGGGAAAGCGG-3, andfrom GenBank, and the fragments were ligated into pGL3basic vector. Muta-
the forward primer for ITF-2B was: 5-TCCAGGTTTGCCATCTTCAGT-3. Fortions in presumptive TCF DNA binding sites in the proximal region of the
both transcripts, the reverse primer was 5-GCCTGGCGAGTCCCTATTG-rat and human ITF-2B promoters were generated by a standard PCR-based
3, and the Taqman probe was 5-TATGCTCCATCAGCAAGCACTGCCG-3mutagenesis approach. A full length human ITF-2B cDNA was amplified by
(Applied Biosystems), with a carboxyfluorescein label at the Taqman probePCR from a human colon cancer cDNA and cloned into the retroviral vector
5 end and a carboxytetramethyl rhodamine label at its 3 end. ExpressionpPGS-CMV-CITE-Neo (Kolligs et al., 1999). All plasmid sequences were
of the hypoxanthine phosphoribosyl transferase (HPRT) housekeeping geneconfirmed by automated sequencing of double-stranded DNA templates.
was used to normalize the ITF-2A and ITF-2B data. For HPRT, the forward
primer was 5-TTGCTCGAGATGTGATGAAGGA-3, and the reverse primerCell culture
was 5-CCAGCAGGTCAGCAAAGAATT-3. The HPRT Taqman probe was:The HEK293, HT-29, DLD-1, HCT-116, and SW480 cell lines were obtained
5-CCATCACATTGTAGCCCTCTGTGTGCTC-3 (Applied Biosystems), withfrom American Type Culture Collection (Rockville, MD). The amphotropic
5 VicTM and 3 carboxytetramethyl rhodamine labels. Each sample was runPhoenix packaging cell line was obtained from G. Nolan (Stanford University
in duplicate and a minimum of two independent experiments were performedSchool of Medicine), and the HT-29/-gal and HT29/APC lines which were
for each sample. The following PCR conditions were used: one step of 50Cobtained from B. Vogelstein (Johns Hopkins University School of Medicine).
for 2 min, one step of 95C for 10 min, followed by 40 cycles of 15 s atRK3E, RK3E/Neo, RK3E/Tcf-4N31, and RK3E cells neoplastically trans-
95C and 1 min at 60C. Detection of fluorescence was performed duringformed by K-ras, -catenin, and -catenin have been previously described
the run by the ABI system and plotted post-run. The PCRs for ITF-2A,(Kolligs et al., 1999, 2000). All cells were grown in 5% C02 with medium
ITF-2B, and HPRT were performed in adjacent wells. Using the softwarecontaining 10% fetal bovine serum and penicillin/streptomycin, unless other-
accompanying the Prism 7700 detector, the HPRT signals were used forwise stated. The 293, Phoenix, and human colon cancer lines, except for
normalization. The Student’s t test was used to determine the significanceHT-29 lines, were grown in DMEM (Life Technologies, Gaithersburg, MD).
of differences in relative ITF-2A and ITF-2B expression between the 18 OEAsHT29, HT29/-Gal, and HT29/APC cells were cultured in McCoy’s medium
with strong nuclear staining for -catenin and mutations in the -catenin,(Life Technologies), and hygromycin B (Sigma, St. Louis, MO) was included
APC, AXIN1, or AXIN2 genes and the 27 OEAs lacking strong nuclearat a concentration of 0.6 mg/ml for the HT29/-Gal and HT29/APC cells. A
-catenin staining and pathway mutations.clonal RK3E cell line expressing the -catenin S33Y/ER fusion protein was
obtained following retroviral transduction of RK3E cells with supernatants
from amphotropic Phoenix cells transfected with pBabe-S33Y-ER-puro. Immunohistochemical analysis
Immunohistochemical analysis of -catenin and ITF-2 expression in OEAsDrug selection of pBabe-S33Y-ER-puro-transduced RK3E cells was carried
out in puromycin (Sigma, St. Louis, MO) at a concentration of 1.0 g/ml. A was performed essentially as described previously (Wu et al., 2001). In brief,
5 m sections of formalin-fixed, paraffin-embedded tissues were mountedsingle resistant colony was isolated by ring cloning and expanded into a
stable cell line, termed RK3E/S33Y-ER. The RK3E/S33Y-ER line was main- on Probe-On slides (Fisher Scientific, Hanover Park, IL), deparaffinized in
xylene, and then rehydrated into distilled water through graded alcohols.tained in 0.5 g/ml puromycin. To activate the S33Y-ER fusion protein, the
RK3E/S33Y-ER cells were treated with media supplemented with 0.5 M Antigen retrieval was enhanced by microwaving the slides in citrate buffer
(pH 6.0; Biogenex, San Ramon, CA) for 15 min. Endogenous peroxidase4-OH-tamoxifen (4-OHT) (Sigma), made from a stock concentration of 100
M 4-OHT in 100% ethanol. To inhibit new protein synthesis in RK3E/ activity was quenched with 6% hydrogen peroxide in methanol, and the
slides were blocked with 1.5% normal horse serum for 1 hr. For the -cateninS33Y-ER cells, media was supplemented with cycloheximide (Sigma) at a
concentration of 1 g/ml. To assess effects of wild-type APC gene function immunohistochemistry, sections were incubated with a mouse monoclonal
anti--catenin antibody (C19220, Transduction Laboratories, Lexington, KY)on ITF-2A and ITF-2B gene expression, HT29/-Gal and HT29/APC cells
were treated with 150 M of ZnCl2 for induction of the control lacZ and wild- at a dilution of 1:500 overnight at 4C. Slides were washed in PBS, then
incubated with a biotinylated horse anti-mouse secondary antibody for 30type APC genes, respectively. To assess effects of dominant negative TCF-4
on ITF-2A and ITF-2B gene expression, replication deficient retroviruses min at room temperature. For the ITF-2 immunohistochemistry, sections
were incubated overnight at 4C with a 1:500 dilution of polyclonal, affinity-encoding TCF-4N31 were used to transduce HT-29 and DLD-1 cells. Empty
vector (pPGS-CMV-CITE-Neo) control transductions of the colon lines were purified antibodies raised against a bacterially-expressed, gluthathione-S-
transferase fusion protein containing ITF-2B amino acids 461–560 (Ab142),carried out in parallel. The TCF-4N31- and empty vector-transduced cells
were subsequently selected for 7–10 days in 1.0–1.5 mg/ml G418 (Sigma). followed by a biotinlylated goat anti-rabbit secondary antibody at a 1:100
dilution for 30 min at room temperature. Antigen-antibody complexes wereFocus formation assays in RK3E cells were carried out for four weeks, as
previously described (Kolligs et al., 1999). detected with the avidin-biotin peroxidase method using 3,3-diaminobenzi-
dine as a chromogenic substrate (Vectastain ABC kit; Vector Laboratories,
Burlingame, CA). Immunostained sections were lightly counterstained withNorthern blots
hematoxylin and then examined by light microscopy.Total RNA was extracted using TRIZOL (Gibco BRL). Ten g of total RNA
was separated on 1.2% formaldehyde-agarose gels and transferred to Zeta-
Probe GT-membranes (Bio-Rad, Hercules, CA) by capillary action. A 400 Luciferase reporter gene assays
Cells were plated in 35 mm dishes 12 hr prior to transfection. Transfectionsbp fragment of the rat ITF-2 gene, corresponding to sequences present in
both the rat ITF-2A and ITF-2B transcripts, was generated by PCR with were performed with FuGENE6 (Boehringer Manheim, Indianapolis, IN) ac-
cording to the manufacturer’s protocol, using 2 l of FuGENE6 per 1 g ofprimers derived from GenBank accession number U09228, using cDNA
prepared from -catenin-transformed RK3E cells. A 425 bp fragment of transfected DNA. Analysis of TOPFLASH and FOPFLASH activity in the
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is a target of -catenin transactivation in intestinal tumors. Oncogene 18,RK3E/S33Y-ER cell line was performed as previously described for parental
2883–2891.RK3E and -catenin transformed RK3E lines (Kolligs et al., 1999), except that
24 hr after transfection with reporter constructs, fresh medium containing 0.5 Dahmen, R.P., Koch, A., Denkhaus, D., Tonn, J.C., Sorensen, N., Berthold,
M 4-OHT was added. Then, at specific time points (e.g., 6 hr, 12 hr, 24 F., Behrens, J., Birchmeier, W., Wiestler, O.D., and Pietsch, T. (2001). Dele-
hr), dishes were washed with phosphate buffered saline (PBS), and the tions of AXIN1, a component of the WNT/wingless pathway, in sporadic
cells were scraped from the plates and resuspended in reporter lysis buffer medulloblastomas. Cancer Res. 61, 7039–7043.
(Promega, Madison, WI). To assess the response of the rat ITF2 promoter
Dang, C.V. (1999). c-Myc target genes involved in cell growth, apoptosis,constructs to -catenin, 293 cells were transfected with 0.5 g pcDNA3/
and metabolism. Mol. Cell. Biol. 19, 1–11.S33Y -catenin, 0.5 g pCH110, and 0.5 g of the ITF2 promoter construct
or pGL3basic vector. 48 hr after transfection, the dishes were washed with Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J., Suarez, A., and
PBS, and the cells were scraped from the plates and resuspended in reporter Armas, A. (1999). -catenin expression pattern in stage I and stage II ovarian
carcinomas: relationship with -catenin gene mutations, clinicopathologicallysis buffer. To assess the activity of the human ITF-2 reporter gene con-
features, and clinical outcome. Am. J. Pathol. 155, 527–536.structs in the human colon cancer cell lines and the role of TCFs in their
activity, SW480 and HCT116 were cotransfected with 0.5 g of the human Gonza´lez-Gaita´n, M., and Ja¨ckle, H. (1995). Invagination centers within the
ITF-2 reporter or pGL3basic vectors; 0.5 g dominant negative TCF (TCF- Drosophila stomagastric nervous system anlage are positioned by Notch-
4N31) in pPGS-CMV-CITE-Neo or 0.5 g empty pPGS-CMV-CITE-Neo mediated signaling which is spatially controlled through wingless. Develop-
vector; and 0.5 g pCH110. 48 hr after transfection, the dishes were washed ment 121, 2313–2325.
with PBS and the cells were scraped from the plates and resuspended in
Hart, M., Concordet, J.P., Lassot, I., Albert, I., del los Santos, R., Durand,reporter lysis buffer. Luciferase activities were measured in a luminometer
H., Perret, C., Rubinfeld, B., Margottin, F., Benarous, R, and Polakis, P.after adding luciferase assay reagent (Promega) to the cell lysates.
(1999). The F-box protein -TrCP associates with phosphorylated -catenin
-galactosidase activities were determined according to standard methods
and regulates its activity in the cell. Curr. Biol. 9, 207–210.
and were used to control for transfection efficiency.
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